After three rounds of voting by 26 EU ministers on 20 November, it was announced that Amsterdam will be the new location of the EMA after it leaves London. Amsterdam fought off close competition from Milan and Copenhagen, winning a tie-break draw against Milan in the final round.

Amsterdam has been one of the more popular choices for relocation in surveys of staff at the EMA, and this will go some way to addressing disruption caused by the move. The city also boasts excellent transport links and facilities for the hundreds of experts who need to visit the Agency every year

Our Amsterdam partner, Judith Krens, who specialises in life sciences adds:

"Though it is a significant but inevitable loss for the UK, at Taylor Wessing Netherlands we are delighted that the EMA will move to Amsterdam. In my view Amsterdam offers the perfect climate for pharmaceutical companies, experts and of course the EMA employees. At Taylor Wessing we are used to operating cross-border and I am convinced that we will jointly continue to deliver the best and most efficient service to its current and future clients in the life sciences sector".

In a webinar, recorded on the 31 October 2017 (before the decision), Matthew Royle, Tim Worden and Paul England discuss the broader issues raised by Brexit for medicinal product and medical device authorisations and exclusivity rights, including the issues raised by the EMA relocation

Watch the webinar